Condition: Contrast Enhanced Images vs. Non-contrast Images · Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images · Sponsor: UConn Health
This study will evaluate the efficacy and safety of Gadopiclenol, an FDA-approved contrast agent, for visualizing pituitary lesions on MR images by comparing with the comparator, Gadobutrol, a clinically widely used contrast agent. The study is double-blinded, so neither the participants nor the researchers know which contrast agent is being used during each scan to avoid the bias of results.
This description comes directly from the study's public registry record.
Lihong Wang, MD, Ph D · 860-679-7881 · lwang@uchc.edu
Leo Wolansky, MD · 860-387-8252 · wolansky@uchc.edu
Always discuss trial participation with your own doctor first.
| University of Connecticut Health Center | Farmington, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06846853